SI (48) CARL (41) NPCE (23) MOBI (53) ⌘ Pro Terminal →

Orthofix Medical Inc. (OFIX) — RQD Stock Rating Cockpit

$10.24 +1.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.26

Orthofix Medical Inc. (OFIX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $417.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OFIX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Orthofix Medical Inc. (NASDAQ: OFIX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $10.24 (+1.99% 1D, market cap $417.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, OFIX ranks #346 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OFIX compare to SI and CARL in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), OFIX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 68.8%, and ROIC of -12.2%. By comparison, SI (Shoulder Innovations Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -16.1%, cap $425.5M) and CARL (Carlsmed Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $430.6M). Among the 5-stock peer group, OFIX leads on earnings multiple (N/A) while OFIX leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OFIX?

▼

Per OFIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000884624), Orthofix Medical Inc. generated $822.3M in revenue (+2.9% YoY), -$92.2M in net income, and $33.3M in free cash flow against $850.6M in total assets and $157.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.26 (+0.17%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OFIX)Realized 20D OHLCV Swing Band: ±8.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY OFIX SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (21% of score)

Altman Z-Score 1.02 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 0% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.28+3.3% Next Q

Q2 (-2Q)

Grade D$9.59+2% Next Q

Q3 (-1Q)

Grade D$9.78+4.7% Next Q

Current

Grade D$10.24-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OFIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OFIX currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.39) and Max Pain ($10.75) forces dealer call-delta covering toward $17.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OFIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OFIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

57.530 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

1.02>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE20% OF RANGE

L: $9$10.24H: $17

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on OFIX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-12.2% ROIC with 68.8% gross margin and 7.99% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 1.02 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

20/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like OFIX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OFIX)

✓Walkthrough of OFIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OFIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.74%⚡ TESTING RESISTANCE

2026-11-02O $10.04H $10.24L $10.04C $10.24VOL 399.3K

RES: $10.56SUP: $8.32SMA50: $9.39SMA200: $11.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OFIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OFIX Butterfly Map → + Track OFIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OFIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OFIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OFIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OFIX)

Health Care Rank #346 of 1016 ⚔️ SI vs OFIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OFIX vs. SI, CARL, NPCE, MOBI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Orthofix Medical Inc. (OFIX) ranks #346 by composite RQD confidence (47/100, grade D) and #475 by equity capitalization ($417.1M). Within this direct 5-issuer industry benchmark cohort, OFIX leads on earnings valuation at N/A trailing P/E, while OFIX leads on capital efficiency and profitability with -12.2% ROIC and 68.8% gross margin. MOBI currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with OFIX at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OFIX ACTIVE Orthofix Medical Inc.	D	47/100	—	68.8%	-12.2%	+1.99%	$417.1M	Benchmark Subject
SI Shoulder Innovations Inc.	D	48/100	—	76.5%	-16.1%	+4.93%	$425.5M	/si-vs-ofix →
CARL Carlsmed Inc.	D-	41/100	—	75.3%	-35.0%	+3.01%	$430.6M	/carl-vs-ofix →
NPCE Neuropace Inc.	E	23/100	—	77.2%	-23.0%	+0.62%	$446.6M	/npce-vs-ofix →
MOBI Mobia Medical Inc.	D+	53/100	—	—	—	-4.41%	$375.2M	/mobi-vs-ofix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000884624

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Orthofix Medical Inc. (OFIX) reported GAAP revenue of $822.3M (+2.9% vs. FY2024 revenue of $799.5M , and +10.1% cumulative change since FY2023) , GAAP net income of -$92.2M, operating cash flow of $33.3M, and free cash flow of $33.3M (+29.3% YoY). On the balance sheet, OFIX closed FY2025 with $850.6M in total assets against $157.4M in total debt (Altman Z-Score: 1.02, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$822.3M	-$92.2M	$33.3M	$33.3M	$850.6M	$157.4M
FY2024 (FY)	2024-12-31	$799.5M	-$126.0M	$25.8M	$25.8M	$893.3M	$157.0M
FY2023 (FY)	2023-12-31	$746.6M	-$151.4M	-$45.8M	-$45.8M	—	—

3. OFIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OFIX compare to SI and CARL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OFIX?

Where is OFIX trading relative to its 50-day, 200-day, and 52-week technical levels?

OFIX last traded at $10.24 (+1.99% on volume of 399,270 shares), positioning the stock +9.05% above its 50-day simple moving average ($9.39) and -7.58% below its 200-day simple moving average ($11.08). Across its 52-week range of $8.50 to $16.99, OFIX sits at the 20.5% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.5% ($9.37 to $11.11).

OFIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell OFIX stock right now?

Orthofix Medical Inc. (OFIX) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.

What is OFIX's 12-month price target and RQD AI Jury consensus?

OFIX's 12-month base price target is $9.73 (range $7.59 to $17.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OFIX RQD Cockpit OFIX 12M Forecast OFIX Earnings & Move OFIX Dividends & DRIP OFIX Insiders & 13F OFIX Whale Options OFIX Profit Sankey OFIX News & Why